Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.
You may also be interested in...
Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Approval marks the eighth indication for docetaxel in five different tumor types.
Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Approval marks the eighth indication for docetaxel in five different tumor types.
Bristol Boosts ImClone Funding To Accelerate Erbitux Development
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.